Cell line · CVCL_1415
Papers48
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 48
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PTTG1 drives intestinal-type gastric cancer progression via G2/M checkpoint-mediated cell-cycle reprogramming. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing platinum-based chemotherapy efficacy and safety through combination therapy-mediated remodeling of autophagic homeostasis in gastric cancer. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MTSS1-dependent ubiquitin modifications mediated by FBXO44 remodel the actin cytoskeleton to promote gastric cancer progression. | Mol Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sustained reductions in valine and isoleucine mediate anti-cancer pharmacological effects of inhibiting amino acid transporter LAT1 in cancer cells. | Cancer Metab | 2025 | Its Methods give the RRID and name the line | PubMed | |
| An LCN2-Dependent Positive-Feedback Loop Between Gastric Cancer Cells and Tumor-Associated-Macrophages Mediates Lymphangiogenesis and Lymphatic Metastasis. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Intratumoral Fusobacterium nucleatum Recruits Tumor-Associated Neutrophils to Promote Gastric Cancer Progression and Immune Evasion. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| De novo identification of universal cell mechanics gene signatures. | Elife | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Predictive biomarkers for metachronous gastric cancer development after endoscopic resection of early gastric cancer. | Cancer Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer. | Mol Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Blockade of CHRNB2 signaling with a therapeutic monoclonal antibody attenuates the aggressiveness of gastric cancer cells. | Oncogene | 2021 | Cellosaurus cites it | PubMed | |
| Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer. | Clin Transl Med | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer. | Mol Cancer | 2020 | Cellosaurus cites it | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1415/papers